Vaughan Nelson Investment Management L.P. Has $2 Million Holdings in AbbVie Inc. $ABBV

Vaughan Nelson Investment Management L.P. cut its position in shares of AbbVie Inc. (NYSE:ABBV) by 58.6% in the fourth quarter, Holdings Channel reports. The firm owned 8,760 shares of the company’s stock after selling 12,375 shares during the period. Vaughan Nelson Investment Management L.P.’s holdings in AbbVie were worth $2,002,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. acquired a new position in AbbVie during the third quarter worth $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC acquired a new position in AbbVie during the 3rd quarter worth $33,000. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABBV. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Piper Sandler raised their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Guggenheim reissued a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is owned by company insiders.

AbbVie Stock Performance

Shares of ABBV stock opened at $217.39 on Wednesday. The firm has a fifty day moving average of $222.00 and a 200-day moving average of $224.65. The stock has a market cap of $384.38 billion, a price-to-earnings ratio of 92.11, a P/E/G ratio of 0.74 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is presently 293.22%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: BMO/analyst reaffirmation: BMO maintained a Buy on ABBV with a $258 target, citing immunology strength, strategic M&A and confidence in managing patent headwinds — this supports upside expectations. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Allergan Aesthetics promotions and safety data: marketing pushes (CoolMonth discounts) and AAD poster data on aesthetics products can help near-term revenue and consumer demand in the aesthetics division. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®
• Positive Sentiment: Lower corporate cash taxes across US companies: analyses show a multibillion-dollar drop in cash taxes after recent tax changes — a tailwind to free cash flow and net income for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Upcoming earnings call (April 29): Management will report Q1 results and the FY guidance cadence remains the main near-term catalyst; investors are positioning ahead of the print. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Market context: reports note ABBV shares have risen recently but still underperform broader market — indicating selective investor interest and potential for mean reversion or further outperformance depending on upcoming results. AbbVie Inc. stock rises Tuesday, still underperforms market
• Negative Sentiment: Litigation around Cerevel deal: a court ordered Pfizer and Bain to litigate a suit by Cerevel investors over AbbVie’s deal — increased legal/transactional scrutiny could raise deal costs or disclosure risk. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Oncology headwinds: analyst commentary flags pricing pressure on Imbruvica that could blunt oncology revenue growth in 2026 despite contributions from newer oncology assets. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Competitive oncology moves: Merck’s recent oncology acquisition strengthens a rival pipeline, adding competitive pressure to long-term oncology growth assumptions. Merck Just Made a Big Bet on a New Cancer Growth Engine

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.